3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Conditions
Neuroendocrine Tumors
2
Thymus Neoplasms
1
Interventions
pembrolizumab
133
Carboplatin
132
Cisplatin
119
Paclitaxel
104
Gemcitabine
89
Specimen Handling
82
Magnetic Resonance Spectroscopy
82
Docetaxel
73
Dexamethasone
60
Cyclophosphamide
60
Pemetrexed
57
durvalumab
55
Bevacizumab
55
Capecitabine
54
Radiotherapy
51
Doxorubicin
51
Oxaliplatin
50
Fluorouracil
48
Radiation
47
Rituximab
43
Leucovorin
43
Vincristine
41
Lenalidomide
40
Etoposide
39
atezolizumab
37
Nivolumab
37
Letrozole
36
130-nm albumin-bound paclitaxel
32
Bortezomib
31
Prednisone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
90 days
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts